JSPR Jasper Therapeutics, Inc. Stock Quote

JSPR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	25.70%	Shs Outstand	12.50M	Perf Week	106.28%
Market Cap	626.75M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	64.04%
Income	-4.30M	PEG	-	EPS next Q	-	Inst Own	57.10%	Short Float	-	Perf Quarter	65.52%
Sales	-	P/S	-	EPS this Y	-986.70%	Inst Trans	120.08%	Short Ratio	0.06	Perf Half Y	65.86%
Book/sh	6.90	P/B	2.38	EPS next Y	-	ROA	-4.30%	Target Price	-	Perf Year	65.03%
Cash/sh	0.01	P/C	2089.17	EPS next 5Y	-	ROE	-4.80%	52W Range	7.11 - 18.24	Perf YTD	64.04%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-9.98%	Beta	-
Dividend %	-	Quick Ratio	1.30	Sales past 5Y	-	Gross Margin	-	52W Low	130.94%	ATR	2.59
Employees	24	Current Ratio	1.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	66.18	Volatility	38.41% 26.96%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-4.00%	Profit Margin	-	Rel Volume	17.42	Prev Close	12.48
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.05M	Price	16.42
Recom	-	SMA20	58.09%	SMA50	62.10%	SMA200	63.15%	Volume	35,656,400	Change	31.57%

Oct-13-21

Initiated

Oppenheimer

Outperform

$21

Oct-15-21 09:39PM

Jasper Therapeutics Stock Is up 127% in Three Days. How Much Higher Can It Go?

TipRanks +31.57%

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience